Health

New CAR T Cell Therapy: Know how it’s 90% effective in blood cancer

WhatsApp Channel     Join Now
Telegram Channel     Join Now

New CAR T cell therapy: Learn how it is 90% effective in blood cancer. Experts from Bombay IIT and Tata Memorial Hospital have developed new CAR T cell therapy for blood cancer.

New CAR T cell therapy is much more economical than foreign therapy and has less side effects. In this therapy, immune cells are removed from the patient’s body. And they are used in genetically modified cells.

In this article, know how the new CAR T cell therapy, discovered by IIT Bombay and Tata Institute, is up to 90% effective in blood cancer.

There is good news for those patients suffering from blood cancer. On whom the current treatment is ineffective. Experts from IIT Bombay and Tata Memorial Hospital have jointly developed new CAR T cell therapy.

Which is emerging as a new hope in curing patients. This therapy is 99 percent effective in children, while it is quite effective in adults also.

Doctors have claimed that this is the first new CAR T cell therapy made in the country. Which is very economical compared to the therapy available abroad. And new CAR T cell therapy is side effects are also very less.

Trial conducted in 2 phases of new CAR T cell therapy

India’s new CAR T cell therapy is up to 90% effective in blood cancer. And the chances of its side effects are also very minimal. Let us know about its trial.

Dr. Hasmukh Jain, oncologist of the world famous Tata Memorial Hospital, said that we have trialled this new CAR T cell therapy in two phases.

Fisrt phases Trial for sefty purpose

According to the doctor of the Tata Memorial Hospital, this new CAR T cell therapy was trialled in the first phase regarding safety.

The therapies available abroad have neurotoxicity, which affects the brain. And secondly, side effects like cytokine release syndrome have been seen.

But both side effects were not found in our new CAR T cell therapy. Which is quite beneficial.

Second phases trial on Those in whom standard therapy has failed

In the second phase, we tested this new CAR T cell therapy on those patients. On whom standard therapy has failed.

These also include those patients who have less than 6 months left to live. We have found 70 percent positive results in such patients.

New CAR T cell therapy: 99% successful in children

New CAR T cell therapy has excellent response in children. Dr. Gaurav Narula, Pediatric Oncologist of Tata Hospital, who is trialling this therapy on children, said. That this trial, which was started in June 2021, had very good results for the children.

Children in whom BMT and chemotherapy were not successful and the cancer returned. New CAR T cell therapy was tested on those children.

The treatment had a good effect on 99 percent of the children. The best part is that CAR T cells remain in the body. And it also proves helpful in preventing the return of cancer.

In New CAR T cell therapy, good cells will kill bad cells

Dr. Jain told that in CAR T cell therapy, we remove immune cells from the patient’s body. Cells are genetically modified in the lab by IIT engineers.

A gene is introduced into the cells. Which has two important features. First, good cells, which were growing slowly in the body. He will grow fast.

The second feature of the new CAR T cell therapy is that it effectively targets and destroys cancer cells. After the lab process is completed, CAR T cells are transfused into the patient.

Actually, the treatment is done in one cycle only. But if needed, you can do another cycle also. Like platelets are transfused. CAR T cell are also administered in the same manner. Simply the settings of the machine are different.

New CAR T cell therapy has low side effects and cost

According to Dr. Jain of the Tata Memorial Hospital, in New CART cell therapy, immune cells are removed from the patient’s body. Cells are genetically modified in the lab by IIT Bombay engineers.

The cost of genetically modified cells used in this therapy is Rs 3 to 4 crore.

The lowest priced product is available only in China and Israel for Rs 80 lakh to Rs 1 crore. Apart from this, there are also clinical expenses.

Like if there are any side effects while giving therapy then correcting them etc.

This new CART cell therapy product is indigenous. Therefore its price will be Rs 40 to 50 lakh. This is 10 percent of the cost of therapy sold in the USA.

Doctors and engineers were doing research for this indigenous New CART cell therapy since 2013

Dr. Gaurav Narula, Dr. P. Rahul and Dr. Hasmukh Jain of Tata Hospital worked on pre-clinical trials in collaboration with IIT from 2013 to 2020.

Where this new CAR T cell therapy was created. And many organizations extended their helping hand in this. In 2020 we got permission to test it on humans.

The second phase was started in December 2022 and completed in August. The first approval was received abroad in 2017.

It was available in USA, Europe, China. Now this therapy has got approval for the first time in the country.

New CART cell therapy will be available in 2 months

Approval has been received from the Drugs Controller General of India (DCGI) for the use of new CAR T cell therapy. According to doctors, now some minor approvals including State FDA are pending.

This process will be completed in one and a half to two months. Talks are going on among senior officials of Tata Memorial Hospital regarding this, so that the patient gets treatment at an affordable rate.

Read more articles-

😍
Love
😢
Sad
😮
Surprise
😉
Wink
Admin
                   

Leave a comment